Prognostic value of urokinase plasminogen activator for prostatic carcinoma.
The usefulness of routine clinical application of the urokinase plasminogen activator in prostate cancer was evaluated. The urokinase values of prostate cancer confined to the organ, with extraprostatic spread and with metastatic disease did not differ and showed no significant difference in comparison with benign prostatic hyperplasia. Urokinase is not a useful parameter in clinical routine.
Lehmann
K
K
Urologic Clinic, University Hospital Zürich, Switzerland.
Plas
E
E
Gautschi
K
K
Hauri
D
D
D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010744:Phosphoric Monoester Hydrolases / Q000097:blood; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000097:blood / Q000175:diagnosis* / Q000601:surgery; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000601:surgery; D014568:Urokinase-Type Plasminogen Activator / Q000097:blood*
D015415:Biomarkers; D014408:Biomarkers, Tumor; D010744:Phosphoric Monoester Hydrolases; D014568:Urokinase-Type Plasminogen Activator; D017430:Prostate-Specific Antigen